AIRLINK 59.74 Decreased By ▼ -0.46 (-0.76%)
BOP 6.27 Increased By ▲ 0.02 (0.32%)
CNERGY 4.39 Increased By ▲ 0.33 (8.13%)
DFML 15.91 Increased By ▲ 0.16 (1.02%)
DGKC 71.25 Increased By ▲ 3.00 (4.4%)
FCCL 18.44 Increased By ▲ 0.82 (4.65%)
FFBL 26.10 Increased By ▲ 0.60 (2.35%)
FFL 9.15 Increased By ▲ 0.06 (0.66%)
GGL 10.33 Increased By ▲ 0.48 (4.87%)
HBL 114.80 Decreased By ▼ -0.20 (-0.17%)
HUBC 111.86 Decreased By ▼ -0.14 (-0.13%)
HUMNL 6.65 Increased By ▲ 0.10 (1.53%)
KEL 4.79 Increased By ▲ 0.26 (5.74%)
KOSM 4.68 Increased By ▲ 0.16 (3.54%)
MLCF 38.89 Increased By ▲ 0.99 (2.61%)
OGDC 123.17 Increased By ▲ 2.62 (2.17%)
PAEL 21.92 Increased By ▲ 0.17 (0.78%)
PIAA 10.95 Increased By ▲ 0.05 (0.46%)
PIBTL 5.99 Decreased By ▼ -0.03 (-0.5%)
PPL 108.34 Increased By ▲ 1.54 (1.44%)
PRL 28.12 Increased By ▲ 0.77 (2.82%)
PTC 11.07 Increased By ▲ 0.52 (4.93%)
SEARL 51.55 Decreased By ▼ -0.45 (-0.87%)
SNGP 67.81 Increased By ▲ 0.91 (1.36%)
SSGC 11.56 Increased By ▲ 0.03 (0.26%)
TELE 8.07 Increased By ▲ 1.02 (14.47%)
TPLP 11.72 Increased By ▲ 0.16 (1.38%)
TRG 75.71 Decreased By ▼ -5.04 (-6.24%)
UNITY 22.75 Increased By ▲ 1.60 (7.57%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 6,545 Increased By 61.1 (0.94%)
BR30 22,298 Increased By 199.8 (0.9%)
KSE100 63,703 Increased By 484.4 (0.77%)
KSE30 21,508 Increased By 202.1 (0.95%)
World

US to distribute 4 million J&J Covid vaccines by Tuesday

  • Overall, among 39,321 participants across all regions, the efficacy against severe Covid-19 was 85.4 percent, but it fell to 66.1 percent when including moderate forms of the disease.
Published March 1, 2021

WASHINGTON: Four million doses of the latest Covid-19 vaccine to get US approval will be delivered across the country as early as Tuesday, a senior administration official said.

The United States on Saturday authorized Johnson & Johnson's Covid vaccine for emergency use, boosting President Joe Biden's plan to battle the outbreak that has killed more than 500,000 Americans.

The single-shot vaccine -- the third type to be authorized -- is highly effective in preventing severe Covid-19, including against newer variants, the Food and Drug Administration (FDA) said before giving it a green light.

"Starting tonight, 3.9 million doses of J&J will be distributed across all channels -- states, tribes, territories, and pharmacies and community health centers. Those J&J doses will be delivered as early as this Tuesday morning," the administration official said Sunday on a call with reporters.

"That's the entirety of J&J's current inventory," the official added. "J&J expects to deliver approximately 16 million additional doses by the end of March. So that's a cumulative 20 million."

The J&J vaccine is the third to be greenlighted in the United States after Pfizer's and Moderna's were provisionally approved in December.

Over 65 million people in America have so far received at least one shot of either the Pfizer or Moderna vaccines -- but unlike those, the J&J vaccine requires just one dose, and is stored at fridge temperatures, offering logistical and practical advantages.

The J&J shot appears less protective than Pfizer and Moderna's two-shot regimens, which both have an efficacy of around 95 percent against all forms of Covid-19 from the classic coronavirus strain. In large clinical trials, the J&J vaccine's efficacy against severe disease was 85.9 percent in the United States, 81.7 percent in South Africa, and 87.6 percent in Brazil.

Overall, among 39,321 participants across all regions, the efficacy against severe Covid-19 was 85.4 percent, but it fell to 66.1 percent when including moderate forms of the disease.

All three vaccines have been shown to fully protect against hospitalizations and death, however.

J&J had earlier announced it aims to deliver 20 million doses by the end of March, with 100 million by June -- though the US is pushing to expedite that timeline.

Comments

Comments are closed.